ApprovedFDA approved

Modafinil

FDA-approved wakefulness-promoting agent (Provigil). Selective DAT inhibitor, Rx for narcolepsy, sleep apnea, shift-work disorder.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

WHAT IS MODAFINIL?

Detailed overview

Modafinil is a selective dopamine transporter (DAT) inhibitor synthesized in 1976 in France. The FDA approved it for narcolepsy in 1998, later expanding the label to obstructive sleep apnea and shift-work sleep disorder. Unlike classic stimulants, it acts via the histaminergic tuberomammillary nucleus (TMN) and the orexin system as well, showing lower euphoric affinity. Used off-label for ADHD and cognitive enhancement, although the latter is not an approved indication.

Mechanism

Selective DAT inhibitor

Half-life

12-15 hours

Onset

30-60 min

Legal status

FDA Rx (Provigil)

FDA boxed warning

Severe skin reactions (SJS/TEN/DRESS)

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Headache (most common side effect, dose-dependent)
  • Insomnia, sleep disturbance (especially with late-afternoon dosing)
  • Anxiety, nervousness, irritability
  • Decreased appetite, nausea, dry mouth
  • Mild increase in blood pressure and heart rate, palpitations
  • Rare but serious skin reactions (SJS, TEN, DRESS, FDA boxed warning)
  • Tolerance and psychological dependence with chronic daily use

Contraindications · 6

  • Serious cardiovascular disease: unstable angina, arrhythmia, left ventricular hypertrophy, prior stimulant-associated cardiac issues (FDA Provigil label)
  • History of serious skin reaction (SJS, TEN, DRESS) or modafinil hypersensitivity
  • Hormonal contraceptives: CYP3A4 induction reduces efficacy, backup contraception needed (during and 1 month after treatment)
  • Pregnancy (FDA category C) and breastfeeding: avoid, limited safety data
  • Warfarin interaction: INR monitoring needed; CYP2C19 inhibition can raise phenytoin levels
  • Uncontrolled hypertension; dose reduction with severe hepatic or renal impairment

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Modafinil?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: June 19, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.